早期应用参芎注射液对急性冠脉综合征患者血清白细胞介素-18和高敏C反应蛋白的影响  

Influence of Shenxiong injection applied early on serum IL-18 and hs-CRP in patients with acute coronary syndrome

作　　者：李海苗[1] 袁明远[1] 吴朝晖[1] 

机构地区：[1]武警广东省总队医院,广东广州510507

出　　处：《现代中西医结合杂志》2008年第26期4060-4061,共2页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的探讨早期应用参芎注射液对急性冠脉综合征患者血清白细胞介素(IL)-18、高敏C反应蛋白(hs-CRP)的影响。方法60例急性冠脉综合征患者随机分为参芎注射液组和常规治疗组各30例。治疗1周前后分别测定血清IL-18和hs-CRP。结果参芎注射液组治疗1周后血清IL-18及hs-CRP均明显下降(P均<0.05)。结论早期应用参芎注射液治疗可降低急性冠脉综合征患者的血清IL-18和hs-CRP水平;参芎注射液的抗炎作用明显,急性冠脉综合征患者早期应用参芎注射液治疗可能获益较大。Objective It is to discuss the influence of Shenxiong injection applied early on serum interleukin （IL） - 18 and high sensitive C reactive protein （hs- CRP） in patients with acute coronary syndrome （ACS）. Methods 60 ACS patients were randomly divided into Shenxiong injection group and conventional therapy group. In each group there were 30 cases. Serum IL- 18 and hs - CRP in the two groups were determined before treatment and after treatment for one week. Results Serum IL- 18 and hs- CRP in Shenxiong injection group were obviously lowered after treatment for one week （P 〈 0.05）. Conclusion Shenxiong injection applied early can lower serum IL- 18 and hs- CRP levels in ACS patients. The anti-inflammatory effect of Shenxiong injection is obvious. Shenxiong injection applied early on ACS patient maybe benefit significantly.

关 键 词：急性冠脉综合征 参芎注射液 白细胞介素-18 高敏C反应蛋白 

分 类 号：R543.3[医药卫生—心血管疾病]